A Florida heart transplant recipient died of heart failure after waiting two months for CHAMPVA to approve antirejection drugs needed daily to protect his transplanted heart, underscoring how insurer and plan changes can interrupt access to specialty medications after only a few missed days. The case, involving a Department of Veterans Affairs-administered program, comes as premium increases, expired federal subsidy support, and tighter Medicaid access push more patients to switch coverage.

The Move

• Derion Blackman and his wife switched from a Federal Employees Health Benefits plan to CHAMPVA after their monthly premium was set to more than double to $307 and their deductible also rose.

• After the new coverage began in January, Blackman encountered repeated approval and coordination problems for transplant antirejection medications; his wife said he ran out before his death in March.

• CHAMPVA had his old insurance listed as primary for six weeks, and some prescriptions were delayed pending provider clarification.

• Many insurers have voluntarily said they will honor existing prior authorizations for 90 days after a patient switches plans, but that protection is not universal and may not prevent disruptions in practice.

Why it Matters for Care

• For transplant recipients and other patients on specialty drugs, even a short interruption can trigger severe, life-threatening consequences; in this case, missed antirejection therapy preceded fatal Heart Failure (CHF).

• Clinicians should expect formulary changes, prior authorization resets, and pharmacy benefit confusion when patients change insurers, even if the drug regimen is longstanding.

• Transitions can also alter access to oncology supportive meds, injectables, and subspecialty follow-up, as shown by another patient who reported reduced injection frequency and worsening blood counts after coverage changes.

• At the bedside, early medication reconciliation, rapid submission of prior auth paperwork, and explicit counseling before open enrollment or job-loss transitions may help avert treatment gaps.

Between the Lines

• Lower-premium plans often trade off with narrower networks and less generous drug coverage, shifting administrative burden onto patients, prescribers, and specialty pharmacies.

• The U.S. coverage landscape remains fragmented: insurers, clinicians, hospitals, and drugmakers negotiate separately, creating nonstandard rules that can derail continuity of care.

• Continuity-of-care protections in federal rules and most states are stronger for network terminations than for patient-initiated plan switching during open enrollment or after life events.

• No single actor is strongly incentivized to smooth these transitions, so delays in coverage verification, appeals, and prescription clarification can become clinically meaningful.

What to Watch

• Whether federal agencies or Congress strengthen continuity-of-care requirements for patients who voluntarily switch plans, especially around prior authorization carryover for specialty drugs.

• How Trump administration Medicaid access changes and the lapse of pandemic-era ACA subsidies affect churn, coverage loss, and downstream medication interruptions.

• Whether the VA or CHAMPVA faces added scrutiny over coordination, appeals, and communication for high-risk patients dependent on expensive chronic therapies.

• For clinicians, the practical milestone is the next enrollment cycle: more patients may seek guidance on whether a cheaper plan will still cover transplant, oncology, and other specialty medications without interruption.

Source: KFF Health News